论文信息 - Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer - 字舞流文

Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

O. von Ahsen | C. Kneip | K. Ziegelbauer | C. Lange | J. Schuhmacher | Jörg Müller | H. Apeler | J. Willuda | C. Peña | P. Carrigan | Gabriele Leder | K. Mclean | S. Golfier | J. Tebbe | H. Lerchen | Lars Linden | B. Stelte-Ludwig | F. Dittmer | B. Kreft | C. Kopitz | R. Jautelat | R. Beier | Sherif El Sheikh